SCHEMBL3096410

SCHEMBL3096410

O=C(Nc1ccc(CC(C(=O)NS(=O)(=O)c2ccc3ccccc3c2)C(=O)N2CCOCC2)cc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.51
KMT2A Q03164 9/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
MEN1 O00255 7/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
MAPK1 P28482 2/20 0.49
ALDH1A1 P00352 3/20 0.47
HTT P42858 2/20 0.47
HPGD P15428 1/20 0.47
F2 P00734 1/20 0.44
MMP9 P14780 1/20 0.44
HIF1A Q16665 1/20 0.44
EPAS1 Q99814 1/20 0.44
GPR27 Q9NS67 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PLG P00747 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3101110 0.92 F10 (0.50) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL3096727 0.91 F10 (0.51) F2MMP9GPR27PLG
SCHEMBL3089259 0.90 NPC1 (0.46) NPC1RAB9AALDH1A1F2MMP9
SCHEMBL3092893 0.87 MMP8 (0.53) MMP8KMT2AMEN1MAPTLMNA
SCHEMBL3093022 0.86 MMP9 (0.55) KMT2ANPC1RAB9AMEN1LMNA
SCHEMBL3090741 0.84 MMP8 (0.50) MMP8KMT2AMEN1MAPTLMNA
SCHEMBL3103341 0.81 MMP9 (0.48) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL3090460 0.80 MMP9 (0.49) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL3102701 0.80 AR (0.49) MMP8NPC1RAB9ALMNAMAPK1
SCHEMBL3102970 0.80 MMP9 (0.46) KMT2ANPC1RAB9AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MMP8 3060/4885KMT2A 1948/4885NPC1 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.